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Abstract
Chronic traumatic encephalopathy (CTE) is a neurodegenerative
disorder associated with exposure to head trauma. In 2015, a panel
of neuropathologists funded by the NINDS/NIBIB defined preliminary consensus neuropathological criteria for CTE, including the pathognomonic lesion of CTE as “an accumulation of abnormal
hyperphosphorylated tau (p-tau) in neurons and astroglia distributed
around small blood vessels at the depths of cortical sulci and in an irregular pattern,” based on review of 25 tauopathy cases. In 2016, the
consensus panel met again to review and refine the preliminary criteria, with consideration around the minimum threshold for diagnosis
and the reproducibility of a proposed pathological staging scheme.
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Eight neuropathologists evaluated 27 cases of tauopathies (17 CTE
cases), blinded to clinical and demographic information. Generalized estimating equation analyses showed a statistically significant
association between the raters and CTE diagnosis for both the
blinded (OR ¼ 72.11, 95% CI ¼ 19.5–267.0) and unblinded rounds
(OR ¼ 256.91, 95% CI ¼ 63.6–1558.6). Based on the challenges in
assigning CTE stage, the panel proposed a working protocol including a minimum threshold for CTE diagnosis and an algorithm for the
assessment of CTE severity as “Low CTE” or “High CTE” for use
in future clinical, pathological, and molecular studies.
Key Words: Brain trauma, Chronic traumatic encephalopathy,
Neurodegenerative disorders, Tauopathy, Traumatic brain injury.
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INTRODUCTION

also neurofibrillary pathology in the locus coeruleus and nucleus basalis of Meynert. In stage III CTE, larger, confluent
perivascular patches of p-tau-immunoreactive NFTs, dot-like
and thread-like neurites and astrocytic tangles were found at
the sulcal depths, as well as NFTs in the superficial cortical
laminae. Diffusely distributed NFTs were also found in medial
temporal lobe structures, including the hippocampus, entorhinal and perirhinal cortices, and amygdala. There was also
more widespread brainstem p-tau pathology. By stage III,
macroscopic features, such as cerebral atrophy, ventricular enlargement, and abnormalities of the septum pellucidum, were
often found. Neurofibrillary degeneration in stage III CTE involved CA4 and CA2, as well as CA1 of the hippocampus. In
CTE stage IV, cerebral, medial temporal lobe and diencephalic atrophy were found grossly. There was depigmentation
of the substantia nigra and locus coeruleus. Perivascular p-tau
lesions and NFTs were distributed throughout the cerebral cortex, and there was pronounced neurofibrillary degeneration of
the medial temporal lobe, diencephalon and brainstem. In addition, NFTs were found in the cerebellar dentate nucleus, basis pontis and spinal cord. Neuronal loss and gliosis were
prominent in the frontal and temporal cortices. Other pathologic lesions, including myelin and axonal loss, as well as
transactive response DNA-binding protein 43 (TDP-43) pathology were also found in the most severe CTE cases.
In March 2013, the National Institutes of Health (NIH),
supported by the Foundation for NIH’s Sports Health Research Program with funding from the National Football
League (NFL), launched a major effort to define the neuropathologic characteristics of CTE. The first NINDS/NIBIB
consensus panel met in February 2015 to blindly evaluate 25
cases of various tauopathies, including CTE, AD, progressive
supranuclear palsy (PSP), corticobasal degeneration (CBD),
Guamanian parkinsonism dementia complex (GPDC), argyrophilic grain disease (AGD), and primary age-related tauopathy
(PART) using the preliminary criteria proposed by McKee et
al (32). Eight neuropathologists, blinded to all clinical and demographic information, successfully identified CTE pathology amongst 25 cases of various tauopathies and determined
that CTE was a distinct disease. The panel also defined a pathognomonic lesion of CTE as “an accumulation of abnormal
hyperphosphorylated tau (p-tau) in neurons and astroglia distributed around small blood vessels at the depths of cortical
sulci and in an irregular pattern.” In addition, the group defined supportive but nonspecific p-tau-immunoreactive features of CTE (Table 1). Since their publication, the NINDS/
NIBIB criteria for the neuropathological diagnosis of CTE
have been widely adopted and used in neuropathological evaluation of CTE in diverse research brain banks and autopsy
cohorts (18, 23, 32–39).
The NINDS/NIBIB panel convened for a second meeting in Boston, MA, on November 15 and 16, 2016, to further
refine the diagnostic criteria for CTE, including the minimum
threshold for diagnosis. The panel sought to determine
whether CTE pathology could be reliably distinguished from
other neurodegenerative processes common to aging and from
other primary tauopathies, such as aging-related tau astrogliopathy (ARTAG) and PART, based on the preliminary 2015
consensus definition (32). The panel also addressed whether
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Ninety-three years ago, New Jersey medical examiner
Harrison Stanford Martland postulated that repetitive traumatic brain injuries (TBI) sustained during amateur and professional boxing careers could lead to lasting
neuropsychiatric, cognitive and motor sequelae (1, 2). Increasing recognition of this distinct clinical entity, variably referred
to as “punch drunk,” “dementia pugilistica,” and “chronic
traumatic encephalopathy” (3, 4) led to the publication of several neuropathological case reports in the 1950s and 1960s,
and culminated in the 1973 cohort study of 15 male pugilists
by Corsellis, Bruton, and Freeman-Browne (5–11). These
studies collectively detailed cortical atrophy, ventricular enlargement, cavum and fenestrated septum pellucidum, thinning of the corpus callosum, substantia nigra depigmentation,
cerebellar scarring, neuronal loss, gliosis, and argyrophilic
neurofibrillary tangles (NFTs) in neurons of the medial temporal lobe, cortex, and brainstem. In the 1990s, 2 independent research teams described the neuronal pathology of “dementia
pugilistica” consisting of thioflavin-positive and hyperphosphorylated tau (p-tau)-immunoreactive NFTs and neurites
with a predilection to surround small cortical blood vessels at
the depths of sulci (12–15). In 2005 and 2006, the identification of p-tau pathology in middle-aged American football
players by Omalu et al brought worldwide awareness to
chronic traumatic encephalopathy (CTE) and to the concept
that repetitive head trauma sustained in modern day contact
sports could trigger the same neurodegenerative disorder as
boxing (16). Today, CTE pathology has been reported in other
contact sports including soccer (17–19), ice hockey (20), wrestling (21), rugby (19, 22, 23), baseball (17), mixed martial
arts, bull-riding; in military-related activities, including exposure to explosive blasts (24, 25); in repetitive head trauma
resulting from physical abuse (26), “head banging” (15),
poorly controlled epilepsy (15), and “dwarf-throwing” (27),
and even demonstrated following exposure to a single moderate or severe TBI (28–30).
In 2013, a clinicopathological case series of 68 men
with a history of exposure to repetitive head impacts and neuropathological evidence of CTE reported “epicenters” of p-tau
NFTs, astrocytic tangles, and neurites clustered at the depths
of the cortical sulci, ranging in severity from isolated, discrete
foci in the neocortex to widespread p-tau pathology involving
the medial temporal lobe, diencephalon, and brainstem.
McKee et al proposed neuropathological criteria for the diagnosis of CTE and a staging scheme for characterizing the severity of p-tau pathology (20). The method of staging CTE ptau pathology was based on large hemispheric 50-mm-thick
slides immunostained as free-floating sections for p-tau,
largely adopted from Braak’s method of staging p-tau pathology of Alzheimer disease (AD) (31). McKee et al proposed 4
pathological stages of CTE: stages I (mild) thru IV (severe). In
stage I CTE, there were 1 or 2 isolated epicenters of NFTs, astrocytic tangles and dot-like neurites arranged around small
blood vessels at the depths of the sulci, most frequently in the
frontal cortex. In stage II CTE, 3 or more CTE lesions were
found in multiple cortical regions. The lesions were larger and
superficial NFTs were found in adjacent cortices. There was
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TABLE 1. Preliminary NINDS Criteria for the Pathological Diagnosis of Chronic Traumatic Encephalopathy (CTE) (31)

*The second consensus panel made refinements in the description of a pathognomonic lesion. They determined that the perivascular p-tau aggregates should include
neurofibrillary tangles, with or without astrocytes, and that the focus had to be in
deeper cortical layers not restricted to subpial and superficial regions.

p-tau pathology in CTE could be progressively staged in a
consistent neuroanatomical pattern of distribution and burden
as proposed by McKee et al (20).

MATERIALS AND METHODS
Twenty-nine cases of various tauopathies were selected
for evaluation, including CTE (n ¼ 19), ARTAG (n ¼ 4),
AGD (n ¼ 2), PART (n ¼ 2), and mild AD (n ¼ 2). Cases were
selected from the Veterans Affairs—Boston University—Concussion Legacy Foundation (VA-BU-CLF)/Understanding
Neurological Injury and Traumatic Encephalopathy (UNITE)
brain bank in Bedford MA and the Mayo Clinic Brain Bank in
Jacksonville, FL. All cases were selected by individuals not directly involved in the consensus case evaluation (KFB, VEA,
ACM). To assess diagnostic reproducibility, 3 CTE cases previously evaluated in the first consensus conference meeting
were included. The remaining 26 cases (16 CTE, 10 other)
had not been previously evaluated by the participating neuropathologists. CTE cases were selected for a wide range of age
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Required for the diagnosis of CTE (pathognomonic CTE lesion):*
1) Phosphorylated tau aggregates in neurons, astrocytes, and cell processes around small vessels in an irregular pattern at the depths of
the cortical sulci.
Supportive tau-related neuropathological features of CTE:
1) Abnormal tau-immunoreactive pretangles and neurofibrillary tangle
(NFTs) preferentially affecting superficial layers (layers II–III), in
contrast to layers III and V as in AD.
2) In the hippocampus, pretangles, NFTs or extracellular tangles preferentially affecting CA2 and pretangles and prominent proximal dendritic
swellings in CA4. These regional p-tau pathologies differ from the
preferential involvement of CA1 and subiculum found in AD.
3) Abnormal p-tau immunoreactive neuronal and astrocytic aggregates in
subcortical nuclei, including the mammillary bodies and other hypothalamic nuclei, amygdala, nucleus accumbens, thalamus, midbrain
tegmentum, and isodendritic core (nucleus basalis of Meynert, raphe
nuclei, substantia nigra and locus coeruleus).
4) Tau-immunoreactive thorny astrocytes at the glial limitans most commonly found in the subpial and periventricular regions.
5) Tau-immunoreactive large grain-like and dot-like structures (in addition to some threadlike neurites).
Supportive nontau-related neuropathological features of CTE:
1) Macroscopic features: disproportionate dilatation of the third ventricle,
septal abnormalities, mammillary body atrophy, and contusions or
other signs of previous traumatic injury.
2) TDP-43 immunoreactive neuronal cytoplasmic inclusions and dot-like
structures in the hippocampus, anteromedial temporal cortex and
amygdala.
Aging-related tau astrogliopathy (ARTAG) may be present but is neither diagnostic nor supportive (40)

at death (23–82, mean 52.7 years). The selected CTE cases
had been previously evaluated by Boston University UNITE
neuropathologists (ACM, VEA) using a full set of paraffinembedded 10-mm-thick slides and large hemispheric 50-mmthick slides and assigned a CTE stage as previously described
(20). The cases included CTE stage I (n ¼ 1), CTE stage II
(n ¼ 3), CTE stage III (n ¼ 11), and CTE stage IV (n ¼ 4).
Formalin-fixed, paraffin-embedded tissue blocks for
each case were recut and processed into slides from the following brain regions: (1) superior frontal gyrus, (2) dorsolateral superior frontal gyrus, (3) striatum (caudate, nucleus
accumbens, and putamen), (4) temporal pole, (5) superior temporal gyrus, (6) amygdala (with entorhinal cortex), (7) hippocampus (at the level of the lateral geniculate), (8) thalamus
(with mammillary body), and (9) cerebellum (with dentate nucleus), at the Bedford VA Neuropathology Lab. Hematoxylin
and eosin staining with Luxol fast blue counterstain and p-tau
immunohistochemistry were performed on all sampled
regions. Phosphorylated-TDP-43 immunohistochemistry was
performed on the hippocampus and superior temporal gyrus.
Beta-amyloid 42 immunohistochemistry was performed on
the dorsolateral superior frontal gyrus and hippocampus. Bielschowsky silver impregnation was performed on the hippocampus. Immunohistochemistry was performed on a Leica
BOND RX autostainer. Antibodies used were p-tau (AT8;
Pierce Endogen, Rockford, IL; 1:2000), Ab (4G8; BioLegend,
San Diego, CA; 1:100 000; 2-minute formic acid pretreatment), and pTDP-43 (pS409/410 mouse monoclonal; Cosmo
Bio Co, Tokyo, Japan; 1:2000). Sections were incubated with
primary antibodies overnight at 4 C. Subsequently, sections
were treated with biotinylated secondary antibody after 3 PBS
washes and labeled with a horseradish peroxidase substrate kit
(Vector Laboratories, Burlingame, CA), counterstained with
Gill’s hematoxylin (Vector Laboratories H-3401), and coverslipped with Permount mounting medium (Thermo Scientific,
Rockford, IL).
The 29 cases were assigned a unique numeric identifier.
A total of 598 newly processed histologic slides (26 cases with
23 slides per case) were scanned at the Mayo Clinic in Jacksonville, FL by a researcher (KFB), blinded to slide origin and
identity, using an Aperio scanner (Leica Biosystems, Buffalo
Grove, IL). Sixty-seven digital images from 3 CTE cases (23
slides per case; 2 slides unavailable for Case #11) from the
first CTE consensus meeting were also included. The resulting
high resolution (20 magnification) digital images were
uploaded to the Aperio Slide-hosting portal. Slide images
were linked with their corresponding unique numeric identifier, neuroanatomic region, and histologic stain. Information
pertaining to the individual’s name, age, sex, race, clinical diagnosis, clinical symptoms, athletic exposure, or gross neuropathologic features was not accessible to slide evaluators
through the online portal. Assessment of the study slides followed the same parameters as the first consensus. Neuropathologists used digital images of scanned slides prepared by a
single laboratory and were blinded to clinical histories and
gross pathological findings.
Eight neuropathologists (NJC, JFC, DWD, RDF, CDK,
DDP, TDS, JPV) experienced in the pathology of neurodegenerative disorders participated in the evaluation of the digital
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tistic was also calculated to evaluate agreement among the
raters on CTE status before (blinded) and after (unblinded)
raters were provided with the clinical data of the cases. Lastly,
kappa statistic was again calculated to evaluate agreement
among the raters on the stage of CTE before and after raters
were provided with clinical data. Individuals without CTE
were not included in these determinations given that the objective was to evaluate agreement of CTE severity.

RESULTS
The neuropathological and demographic features of the
29 study cases are shown in Table 2. The recut and stained
slides for 2 of the 19 CTE cases (Case #16, CTE stage I; Case
#5, CTE stage II) failed to include diagnostic p-tau pathology,
consequently those 2 cases were removed from analysis. For
the remainder of the cases submitted as CTE (n ¼ 17), the
evaluating neuropathologists were highly successful in detecting CTE neuropathological changes. In the first round, blinded
to clinical data and gross neuropathological features, 88% of
the responses indicated the diagnosis of CTE, and after the
clinical data and gross neuropathological features were supplied, 97% of the responses indicated CTE (Fig. 1). Generalized estimating equation analyses showed a statistically
significant association, with large effect sizes, between the
raters and the cases submitted as CTE for both the blinded
(OR ¼ 72, 95% CI ¼ 19–267) and unblinded rounds (OR ¼
257, 95% CI ¼ 64–1559). Amongst the 8 raters there was also
substantial agreement in the diagnosis of CTE for the blinded
first round (Kappa ¼ 0.63) and there was a notable improvement in agreement for the unblinded second round (Kappa ¼
0.79, substantial agreement).
For 10 of the 17 suspected CTE cases (#1, 6, 7, 8, 9, 15,
17, 21, 23, 25, including 2 cases from the first consensus),
there was perfect agreement among the neuropathologists regarding a CTE diagnosis in both the first and second rounds.
In 2 cases (#20, 27) from the first round, one reviewer gave an
alternate diagnosis of CBD (88% agreement), which was
changed to CTE after the clinical data and gross neuropathology were revealed (100% agreement). In 3 cases (#14,18, 24),
6 of the 8 (75%) reviewers considered the diagnosis to be CTE
in the first round; in the second round, all but one response
identified the case as CTE (95%). The alternate diagnoses included GPDC (2), ARTAG (2), PSP (1), and AGD (1). The
panel re-evaluated and discussed these 5 cases (#14, 18, 20,
24, 27) at the face-to-face meeting and agreed that pathognomonic lesions were present in each case, warranting the diagnosis of CTE. In case #29, 4 of 8 (50%) reviewers considered
the diagnosis to be CTE in the first round; the alternative diagnoses were ARTAG and PART (3) and AGD (1). After review
of the clinical and gross neuropathological information, most
reviewers agreed the diagnosis was CTE, although one reviewer maintained the diagnosis of PART and ARTAG. Review of this case by the panel found that despite a low burden
of p-tau pathology in the cortex, there was a pathognomonic
lesion of CTE in the inferior temporal cortex supporting the
diagnosis of CTE. The panel also suggested the case warranted
additional cortical sampling for greater clarity regarding the
frequency of pathognomonic CTE lesions and cortical NFT

213

Downloaded from https://academic.oup.com/jnen/article/80/3/210/6145887 by Washington University School of Medicine Library (M2) user on 20 December 2022

images. Seven of the 8 neuropathologists had previously performed blinded analysis of the study set in the first CTE consensus conference. The neuropathologists were provided a
tauopathy criteria guide regarding the neuropathologic diagnoses of AD, PART, GPDC, AGD, CBD, PSP, and ARTAG
as well as CTE criteria outlined from the first CTE consensus
conference (32) and the staging scheme proposed by McKee
et al (20). (See Supplementary Material for guides.) Evaluating neuropathologists were not aware of the number of cases
representing each tauopathy (including CTE) or that some of
the cases had been evaluated in the first consensus conference.
Through the Aperio Slide-hosting portal, the neuropathologists evaluated the cases independently at their respective
institutions, in any order and at any pace. For each of the 29
cases, the neuropathologists completed an evaluation form in
which they specified their name, case identifier, whether the
case met CTE neuropathologic criteria (yes or no). If the neuropathologist felt the case met CTE criteria, they specified the
CTE stage (stage I, stage II, stage III, or stage IV) and whether
the case met additional neuropathological diagnoses. If the
neuropathologist felt the case did not meet CTE criteria, they
specified the alternative neuropathological diagnosis. Following complete evaluation of all 29 cases and submission of
evaluation forms to the data core of Boston University School
of Medicine (BUSM), the evaluators were provided additional
information regarding the gross neuropathological features for
each case and clinical summaries, including age and athletic
exposure, and asked to repeat their evaluation. Results from
the second evaluation round were again submitted to BUSM
data core, and the data were anonymously compiled prior to
the in-person meeting. Only neuropathological assessments
submitted to the data core prior to the meeting were included
in the analysis.
A larger panel of neuropathologists, clinicians, and biomedical researchers (including KFB, KDO, WS, IL, WG,
ACM, and the NINDS TBI/CTE Group) convened on November 15–16, 2016 in Boston, MA. Meeting participants
reviewed the clinical vignettes, digitized images of the cases
and results from the neuropathological evaluations to facilitate
group discussion. Based on these discussions, the consensus
panel proposed the minimum threshold for the diagnosis of
CTE, strict features necessary for a “pathognomonic” lesion,
and a methodological workflow for the assessment of CTE.
The panel also developed an algorithm for judging whether
the severity of CTE was “High” or “Low.” They also discussed challenges in CTE characterization in the context of
coexistent neurodegenerative and aging pathologies, as well
as strategies for teaching and disseminating neuropathology
practice measures.
Generalized estimating equation was used to assess the
association between the rater’s diagnosis of CTE (absent/present) and the BU UNITE diagnosis of CTE (absent/present).
The latter had been made prior to the study using a full set of
paraffin-embedded 10-mm-thick slides and large hemispheric
50-mm-thick slides. Generalized estimating equation was performed in order to account for correlations between the raters
for the same case. This association was assessed before
(blinded) and after (unblinded) raters were provided with the
gross neuropathology and clinical data of the cases. Kappa sta-
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TABLE 2. Demographic Features and Evaluation Results of CTE Study Cases
Evaluation (CTE Dx)
Age/Sex

Sport (Duration, Year)

Submission Dx (Stage)

16
23
15
5
14
27
21
17
25
29
1
8
6
7
9
20
18
11
24

23/M
25/M
27/M
38/M
40/M
41/M
46/M
48/M
49/M
53/M
53/M
61/M
66/M
66/M
69/M
68/M
70/M
75/M
82/M

FB (9)
FB (15)
FB (14)
FB (14)
FB (13)
FB (17)
FB (20)
FB (17)
FB (23)
FB (15)
FB (14)
BX (26)
FB (17)
FB (16)
FB (28)
FB (19)
FB (8)
FB (18)
FB (12)

CTE (I)
CTE (II)
CTE (II)
CTE (II)
CTE (III)
CTE (III)
CTE (III)
CTE (III)
CTE (III)
CTE (III)
CTE (III)
CTE (III)
CTE (III)
CTE (III)
CTE (IV)
CTE (IV)
CTE (III)
CTE (IV)
CTE (IV)

Round 1

Round 2

No diagnostic pathology
8/8
8/8
8/8
8/8
No diagnostic pathology
6/8
7/8
7/8
8/8
8/8
8/8
8/8
8/8
8/8
8/8
4/8
7/8
8/8
8/8
8/8
8/8
8/8
8/8
8/8
8/8
8/8
8/8
7/8
8/8
6/8
8/8
4/8
6/8
6/8
8/8

Outcome ()
Eliminated
Low CTE (3)
Low CTE (4)
Eliminated
High CTE (10)
High CTE (7)
High CTE (9)
High CTE (7)
High CTE (9)
High CTE (8)
High CTE (7)
High CTE (10)
High CTE (9)
High CTE (6)
High CTE (10)
High CTE (10)
High CTE (5)
High CTE (8)
High CTE (10)

CTE, chronic traumatic encephalopathy; Dx, diagnosis; FB, football; M, male; Outcome (), the results of the workflow protocol for the assessment of high and low CTE, number in brackets represents the number of regions with NFTs (derived from Workflow Diagram).

burden. Subpial thorn-shaped astrocytes (TSA) at the depths
of the sulci were also a prominent feature of the case. This was
interpreted by the in-person panel as a feature of ARTAG and
not diagnostic for CTE. NFT in the medial temporal lobe were
also found in case #29 and interpreted by one reviewer as consistent with PART. After panel discussion, the group determined that if a case is diagnosed as CTE based on cortical
pathology, the presence of NFT in the medial temporal lobe is
considered a feature of CTE and an additional diagnosis of
PART is not warranted. The group also noted that CA4 p-tau
pathology was uncommon in PART, whereas in CTE, if present, CA4 p-tau pathology consists of pretangles, NFTs and
dendritic dystrophy which can be useful for distinguishing
CTE from PART. Case #11, a case with widespread neuritic
plaques that was also evaluated in the first consensus, also
posed difficulties for the reviewers. Prior to learning the clinical and gross neuropathological information, 3 reviewers
made a diagnosis of AD and one of ARTAG. After learning
the clinical information, 2 reviewers still considered the diagnosis to be AD. Re-assessment of the case by the in-person
panel found that the case satisfied criteria for CTE in that multiple cortical pathognomonic CTE lesions were present. The
cortical NFT burden was predominantly superficial in the temporal lobe; however, the group agreed that the case warranted
a second diagnosis of AD neuropathological change.
In addition, the group discussed the minimum threshold
for the diagnosis of CTE and the pathological features critical
to a strict definition of “pathognomonic CTE lesion.” The
group endorsed a single pathognomonic lesion in the cortex as
the minimum threshold for CTE. The group also endorsed the
following features of the pathognomonic lesion as necessary:
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p-tau aggregates in neurons, with or without concomitant ptau-immunoreactive TSA, at the depth of the sulcus around
small blood vessels, in deeper cortical layers not restricted to
subpial and superficial region (Fig. 1). The panel unanimously
confirmed that, based on case material available, purely astrocytic perivascular p-tau lesions (including subpial ARTAG)
did not meet criteria for CTE (Fig. 2). Furthermore, clusters of
p-tau-immunoreactive astrocytes in the white matter of the
frontal and temporal cortex, basal ganglia, lateral or medial
brainstem were considered consistent with ARTAG (40–43),
and not specific features of CTE.
For the 10 non-CTE cases submitted, 95% of responses
in the first blinded round of evaluation correctly indicated that
CTE was not present. In the unblinded second round, 99% of
the responses correctly indicated that CTE was not present.
The submitted diagnoses on the cases misidentified as CTE
were: ARTAG (2), PART (1), and mild AD (1). The only incorrect response in the second round was a case that had been
submitted as ARTAG.
Evaluators were less consistent assigning a CTE stage.
Unanimous consensus on CTE stage was not reached on any
case in either round of evaluation. Of the 17 CTE cases evaluated, 5 (29%) cases were given a CTE stage by the majority of
neuropathologists that matched the CTE stage originally
assigned by UNITE neuropathologists. This was true for both
first and second rounds of evaluation. For 12/17 CTE cases
(71%), the majority of the neuropathologists assigned a CTE
stage that was one level lower than the UNITE neuropathologists assigned CTE stage. For 2/17 CTE cases, consensus was
split between two CTE stages (one corresponding to the
assigned level). For both rounds, 2 different CTE stages were
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ferior parietal lobule, (4) hippocampus, (5) amygdala, (6) basal
assigned on 5 CTE cases, 3 different CTE stages were
assigned on 11 CTE cases, and for one case (Case #9), neuroganglia, (7) thalamus, (8) midbrain with substantia nigra, (9) pons
pathologists were split between all 4 CTE stages. Amongst the
with locus coeruleus, (10) medulla oblongata, and (11) cerebellar
8 raters, Kappa values were 0.22 and 0.19 for the blinded first
cortex, as recommended by the first consensus conference (32).
round and unblinded second round, respectively.
2. The minimum threshold for diagnosis of CTE is the presence of a
After discussion, the neuropathologists agreed that a
single pathognomonic lesion in the cortex (Fig. 1). A pathognosimple and practical tool for the assessment of CTE pathomonic lesion consists of p-tau aggregates in neurons, with or
logical severity would be helpful for general use. The panel,
without glial tau in TSA, at the depth of a cortical sulcus around a
therefore, proposed an operational workflow for the diagnosis and binary classification of CTE as mild “Low CTE” or
small blood vessel, in deeper cortical layers not restricted to
severe “High CTE” requiring evaluation of a limited numsubpial and superficial region of the sulcus.
ber of paraffin-embedded, 10-mm-thick tissue sections 3. To stage CTE severity, in the cortical region containing the CTE
(Fig. 3).
focus, the presence of NFT in the bank or crest of the gyrus each

Proposed Operational Workflow:

count as 1 point, NFT in the superficial cortical laminae (often
most prominent in the temporal lobe) also count as 1 point.

1. The diagnosis of CTE is made using 10-mm-thick paraffin-

Should multiple CTE foci be present, scoring is to be performed

embedded tissue sections from the following brain regions: (1)

on the single, most definitive CTE focus (i.e. maximum of 3

Middle frontal gyrus, (2) Superior and middle temporal gyri, (3) In-

points from the cortex per case). The presence of NFTs in CA1
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FIGURE 1. Diagnostic lesions of chronic traumatic encephalopathy (CTE) in 4 cases. (A–D) Pathognomonic CTE lesions in 4
cases immunolabeled by the anti-phosphorylated tau antibody AT8. (A) 25-Year-old former collegiate football player (CTE stage
II, case #23). The CTE focus appears neuronal and composed of perivascular NFTs and dotlike neurites surrounding a small
cerebral blood vessel. Glial tau pathology is not immediately evident. (B) A 27-year-old former professional football player (CTE
stage II, case #15). The CTE focus is neuronal and composed of perivascular NFTs and dotlike neurites surrounding a small
cerebral blood vessel. (C) A 40-year-old former professional football player (CTE stage III, case #14). The CTE focus is neuronal
and astrocytic, and composed of p-tau-immunoreactive NFTs, dotlike and threadlike neurites and cellular processes, surrounding
a small cerebral blood vessel. (D) A 69-year-old former professional football player (CTE stage IV, Case #9). The CTE focus is
composed of tau-immunoreactive NFT (black arrowhead), astrocytes (red arrowhead), dot and threadlike neurites and cell
processes surrounding a small cerebral blood vessel. Scale bars: 100 mm.
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4.

5.

6.

7.

and CA4 of the hippocampus, entorhinal cortex, amygdala, thalamus, mammillary body, and cerebellar dentate nucleus also
count as 1 point each for a total of 10 possible points per case.
Cases with <5 points are considered mild cases of CTE (“Low
CTE”; Fig. 1A, B). Cases with 5 or more points are considered
severe cases of CTE (“High CTE”; Fig. 1C, D). This approach
accounts for variability in neuroanatomical patterns of p-tau pathology and distinguishes cases with focal involvement of the
cortex (Low CTE) from those with more widely distributed neurofibrillary pathology (High CTE).
Given the patchy nature of CTE, in instances when CTE is suspected but not evident in the initial slides, additional cortical
sampling is recommended. It is recommended that the
resampled tissue capture 4–8 cortical sulci (preferably bilateral)
from the superior frontal, dorsolateral superior frontal, superior
middle temporal, and/or inferior temporal gyri.
In cases with only subpial p-tau TSA, superficial laminar NFT or
nonspecific sulcal p-tau pathology, the case is not diagnostic for
CTE and resampling is recommended.
If a CTE focus is detected with resampling, the case is diagnosed as CTE and assessed for severity as Low or High CTE. If
no CTE foci are identified with resampling, the case is considered not diagnostic for CTE.
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For the 17 CTE cases evaluated by the consensus panel,
these guidelines accurately categorized the level of severity of
CTE pathology as Low (n ¼ 2) or High (n ¼ 15) (Table 2).

DISCUSSION
Following independent analysis and in-person review of
27 study cases by the panel, including 17 cases of suspected
CTE from subjects (ranging from 25 to 82 years, mean 52.7)
and 10 cases representing ARTAG, PART, AGD, and mild
AD (ranging from 81 to 94 years, mean 88.0), there was strong
agreement in the diagnosis of CTE, both blinded to clinical
and gross neuropathological information and unblinded. These
results confirm the robustness of the consensus recommendations defined by the first NINDS/NIBIB consensus conference
(32). The panel upheld the definition of the pathognomonic lesion of CTE as “phosphorylated tau aggregates in neurons,
astrocytes, and cell processes around small vessels in an irregular pattern at the depths of the cortical sulci”; however, the
panel made several refinements to the criteria. In particular,
based on the case material reviewed, the panel concluded that
the perivascular p-tau aggregates had to include neuronal profiles, with or without p-tau in astrocytes, and that the focus
had to be in deeper cortical layers not restricted to subpial and
superficial regions. In addition, the panel cautioned that subpial TSA or perivascular astrocytic pathology in isolation
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FIGURE 2. ARTAG and CTE p-tau pathology immunolabeled by the anti-phosphorylated tau antibody AT8. (A) Subpial ARTAG
with superficial astrocytic p-tau pathology, not diagnostic of CTE. (B) CTE focus at depth of the sulcus. (C) Subpial ARTAG. (D)
CTE focus at sulcal depth in addition to subpial ARTAG. (Sulcal depths indicated by asterisks; scale bars: 100 mm).
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were consistent with ARTAG and did not meet the minimum
criteria for CTE. However, members of the panel did acknowledge that the exact role of glial tau accumulation in CTE is an
issue requiring further study. The consensus panel agreed that
recognition of CTE pathology was more challenging in older
individuals due to the increased prevalence of aging-related
tau pathologies, notably ARTAG and PART. Communitybased studies from Forrest et al and Bieniek et al together suggest that while cortical ARTAG frequency is notable in the elderly (38%), the presence/absence of CTE pathology varies by
sex and head trauma history in the autopsy cohort evaluated
(36, 44). Furthermore, NFTs in medial temporal structures in
the absence of amyloid plaques are characteristic of both
PART and CTE although there is some suggestion that CA4 ptau pathology is more consistent with CTE. While further
work needs to be done to differentiate CTE medial temporal

lobe p-tau pathology from PART, the panel decided that, for
the time-being, cases with cortical CTE lesions and NFT in
the medial temporal lobe do not warrant an additional diagnosis of PART.
The results of applying the McKee staging system to the
cases in this consensus evaluation proved to be inconsistent.
P-tau pathology of CTE is, by definition, patchy, and diagnostic lesions in mild cases may be widely dispersed in cortical
regions. The McKee CTE staging scheme was originally proposed following review of extended case material, as well as
large hemispheric sections. As such, it is conceivable that the
more limited sampling provided for this consensus review underrepresented the pathology in selected cases. Consistent
with this, the consensus panel failed to identify CTE pathology
in 2 of the cases included for evaluation in which CTE had
previously been diagnosed. While large hemispheric sections
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FIGURE 3. Working protocol for the diagnosis of chronic traumatic encephalopathy (CTE).

Bieniek et al

218

In summary, blinded assessment of 27 cases of various
tauopathies resulted in high diagnostic agreement in cases of
CTE and non-CTE using the NINDS/NIBIB criteria for the diagnosis of CTE (32). However, attempts at CTE staging using
the McKee CTE staging scheme were unsuccessful. In view of
this difficulty assigning CTE stage, the panel proposed an alternate operational workflow for the diagnostic evaluation of
potential CTE cases and a recommendation that CTE p-tau
pathological severity be designated as “High CTE” or “Low
CTE.” Low CTE cases are characterized by cortical pathology, whereas high CTE cases have pathology widely distributed in hippocampus, amygdala, entorhinal cortex, thalamus,
mammillary bodies and cerebellar dentate nucleus. Validation
of the operational workflow for potential CTE cases using additional cohorts and improved identification of CTE in the
presence of comorbid neurodegenerative diseases and agingrelated pathologies remain future objectives.
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offer an improved way to assess global p-tau pathology, the
objective of this study was to develop a practical method of
assessing CTE that would be available to a general pathologist. Given that, this was not entirely unexpected. As a result,
the consensus panel proposed a simplified working protocol
for the assessment of CTE and an algorithm for evaluation of
CTE severity. The algorithm classifies cases with pathognomonic CTE foci as either “Low CTE” or “High CTE,” which
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“Low CTE” roughly equates to CTE stages I and II, and “High
CTE” to CTE stages III and IV. The proposed assessment
scheme for CTE severity is provisional, it does not reflect
NFT burden, and the usefulness of the working protocol will
need to be continuously evaluated in a larger number of CTE
cases to confirm its reliability. Nevertheless, in the small number of CTE cases evaluated by the panel, the proposed algorithm accurately distinguished between mild (Low) and severe
(High) cases of CTE (Fig. 3).
Future measurement of p-tau burden in CTE, as well as
regional involvement, will allow for the comparison of antemortem variables to varying degrees of pathology and facilitate analysis of disease risk factors (e.g. type of exposure,
exposure duration, etc.) and disease modifiers (e.g. genetic
variants, clinical or behavioral therapies, etc.). Neuroanatomical regions assessed in the second consensus meeting were
comparable to the first consensus meeting (for the sake of uniformity and intrarater reliability); however, it should be noted
that proposed workflow from both meetings includes additional structures, notably brainstem, as abnormal subcortical
tau pathology is a supportive feature of CTE (Table 1). Uniform assessment of CTE severity will also permit comparison
between cohorts and centers.
One of the strengths of this study is that all slides were
processed by a single research center, the VA-BU-CLF/
UNITE brain bank, producing consistency in histologic preparation. Similarly, the evaluating neuropathologists were provided the same set of digital images for all cases. In addition,
the neuropathologists evaluated the cases independently, at
their own pace, and in their own sequence. Limitations of the
study are that nearly all CTE cases were former professional
American football players; one was a former college football
player and one was a former professional boxer. Furthermore,
the study cases were relatively “pure” CTE (with the exception of some AD pathology) despite reports indicating that comorbid neurodegeneration (AD, amyotrophic lateral sclerosis,
frontotemporal lobar degeneration, Lewy body disease, multiple system atrophy, etc.) is common in older individuals with
CTE (19, 20, 45–47). Distinguishing CTE from concomitant
neurodegenerative and aging-related pathologies represents a
topic of interest for future studies, and the consensus committee makes no assertions regarding CTE in the presence of AD
or other neurodegenerative disorders at this time. Additional
educational training for general neuropathologists, neuropathology fellows, and biomedical neuroscience researchers regarding the CTE criteria is also another area that needs to be
developed more fully in the future.
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